Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients

For lymphoma patients undergoing treatment, HBV reactivation may occur even if both HBsAg and HBV DNA are negative at the initiation of treatment. It is noteworthy that this study found that patients with HBcAb (-) also experienced HBV reactivation. Therefore, patients who are negative for HBsAg, HBcAb, and HBV DNA should also be closely monitored to mitigate the risk of HBV reactivation.